Investigative and Clinical Urology (Jan 2021)

Comparison of inflammation-based prognostic scores as predictors of survival outcomes in patients with germ cell tumors

  • Kasumi Yoshinaga ,
  • Takuya Sadahira ,
  • Yuki Maruyama ,
  • Yosuke Mitsui ,
  • Takehiro Iwata ,
  • Koichiro Wada ,
  • Motoo Araki ,
  • Toyohiko Watanabe ,
  • Yasutomo Nasu

DOI
https://doi.org/10.4111/icu.20200103
Journal volume & issue
Vol. 62, no. 1
pp. 47 – 55

Abstract

Read online

Purpose: The aim of this study was to compare the prognostic value of pretreatment inflammation-based scoring systems in terms of overall survival (OS) and progression-free survival (PFS) in patients with germ cell tumors (GCTs) receiving bleomycin, etoposide, and cisplatin (BEP) chemotherapy. Materials and Methods: We evaluated 63 patients with GCTs retrospectively. The Glasgow prognostic score (GPS), neutrophil-to-lymphocyte ratio, prognostic index, platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), systemic immune-inflammation index, and albumin-to-globulin ratio (AGR) were measured in all patients before chemotherapy. To assess the predictive ability of each scoring system, areas under the receiver operating characteristic curve were calculated, and multivariate analysis was performed to identify associations between the predictive scores and OS. Results: Of all the inflammation-based scoring systems, the GPS had the greatest area under the curve (0.847) for predicting OS, followed by the PNI (0.829) and AGR (0.810). Kaplan–Meier analyses revealed that the GPS, PNI, and AGR were significantly associated with OS, whereas the GPS, PLR, and PNI were significantly associated with PFS. In the multivariate analysis, the GPS was an independent predictor of OS and PFS. Conclusions: We demonstrated that the GPS was the most valuable biomarker of OS and PFS in patients with GCTs.

Keywords